Pancreatic Cancer
Conditions
Interventions
A:Rabeprazole(10mg/Day)adiminisitration between 8weeks
B:Without administration of any kind of PPI or H2RA
Sponsors
Faculty of Mediceine, University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients who were diagnosed with pancreatic cancer and will receive chomothrapy of GEM or GEM+TS-1 2 Patients more than equal 20 years old 3 Patients who can decide themselves
Exclusion criteria
Exclusion criteria: 1 Patients with gastric ulcer or esophagial varices 2 Lanza score, greater or equal 2 3 Direct invasion to gastric or duodenal mucosa 4 Patients who have the symptom of abdominal pain or heartburn 5 Patients who take NSAIDs or steroids 6 Patients who had taken PPI or H2RA within 14 days before start of chemothrapy 7 Patients who had liver chirrosis 8 Patients who ware given gastric resection 9 Performance status, greater or equal 3 10 Patients who had undertaken adverse event caused by PPI 11 Patients who were determined inadequate by doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Lanza score | — |
Countries
Japan
Contacts
Public ContactYoko Yashima
Tokyo University Hospital Department of gastroenterology
Outcome results
None listed